In this #europcr 2025 discussion, Mayra Guerrero, Thomas Modine, and Philipp Lurz share their views on the evolving landscape of mitral valve treatment.

While transcatheter edge-to-edge repair (TEER) remains a safe and effective approach, it doesn’t work for every patient. That’s why alternatives like TMVR, annuloplasty, or NeoChords—all currently under investigation—are generating attention.

The field is moving toward transseptal, transcatheter options that may deliver better reduction of mitral regurgitation, along with improved symptoms and quality of life. They offer the added advantage of allowing future valve-in-valve procedures if needed.

Should a strong mitral program combine both repair and replacement? How do we decide between the two?

There are still challenges—but innovation is pushing the field forward.

Listen now and get a glimpse of what’s next for mitral therapies!

Hosted on Acast. See acast.com/privacy for more information.